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Identification of 22 susceptibility loci associated
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Testicular germ cell tumors (TGCT) are the most common tumor in young white men and
have a high heritability. In this study, the international Testicular Cancer Consortium
assemble 10,156 and 179,683 men with and without TGCT, respectively, for a genome-wide
association study. This meta-analysis identifies 22 TGCT susceptibility loci, bringing the total
to 78, which account for 44% of disease heritability. Men with a polygenic risk score (PRS) in
the 95th percentile have a 6.8-fold increased risk of TGCT compared to men with median
scores. Among men with independent TGCT risk factors such as cryptorchidism, the PRS may
guide screening decisions with the goal of reducing treatment-related complications causing
long-term morbidity in survivors. These findings emphasize the interconnected nature of two
known pathways that promote TGCT susceptibility: male germ cell development within its
somatic niche and regulation of chromosomal division and structure, and implicate an
additional biological pathway, mRNA translation.
https://doi.org/10.1038/s41467-021-24334-y OPEN
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TGCTs are the most common cancers in young men ofEuropean ancestry, and incidence of TGCT has doubledover the past 20 years1,2. Family history and cryptorchid-
ism are the strongest known risk factors3–5, but no robust
environmental risk factors have been identified1. Despite the high
heritability of TGCT, estimated at 37–49%6,7, CHEK2 is the only
moderate penetrance gene in which pathogenic variants have
been associated with risk of TGCT8.
In contrast, genome-wide association studies (GWAS) have
succeeded in identifying common variation associated with
TGCT susceptibility9–21. Most risk variants map to loci con-
taining genes encoding proteins implicated in critical pathways
for male germ cell development, chromosomal segregation, sex
determination, and DNA maintenance. Biologically these findings
complement the current understanding of disease pathogenesis
involving in utero transformation of fetal germ cells into germ cell
neoplasia in situ (GCNIS), the common precursor of TGCT22,23.
To gain further insight into the genetic underpinnings of
TGCT, the Testicular Cancer Consortium (TECAC) present
results from a large meta-analysis of 10,156 men with TGCT and
179,683 men without TGCT that combined summary data from
numerous extant TGCT GWAS and de novo genotyping from
men with and without TGCT. We identify 22 independent loci for
TGCT (P < 5 × 10−8), many of which map to genes that encode
proteins in pathways related to male germ cell development, sex
determination and chromosomal segregation, as well as mRNA
translation. Polygenic risk score (PRS) analysis of all 78 identified
risk loci to date reveals a 6.8-fold increase in TGCT risk for men in
the top 5% of PRS score compared to those at the median.
Results
Our meta-analysis incorporated estimates from our published
TGCT analysis9, genotyping data from deCODE genetics24 and
the UK Biobank25, and summary statistics from genotypes col-
lected from 14 studies collaborating as part of the Testicular
Cancer Consortium (TECAC) (Supplementary Tables 1, 2; Sup-
plementary Methods). Initial findings were extended by incor-
porating results from targeted genotyping of 1039 men with
TGCT and 1398 men without TGCT (Supplementary Tables 3, 4).
GWAS meta-analysis of TGCT. Our final meta-analysis identi-
fied 22 independent susceptibility loci for TGCT (P < 5 × 10−8)
(Table 1, Fig. 1, Supplementary Fig. 1), including four independent
signals at previously identified genetic regions (Supplementary
Table 5; Supplementary Fig. 2) and four loci on the previously
disregarded X chromosome (Supplementary Data 1). The Q–Q
plot (Supplementary Fig. 3) and estimated genomic inflation
factor (λ= 1.03) suggested minimal systematic bias. Only three
signals (rs9987332, rs8104804, and rs4898474) showed effect
heterogeneity (I2 > 50). Forty-four of the 56 previously identified
TGCT susceptibility loci9–21 replicated at P ≤ 5 × 10−8 (Supple-
mentary Data 2; Supplementary Data 3). Possible reasons for not
replicating all known loci include differences in underlying
population substructure, prior overestimation of genetic effect
size, effect size heterogeneity, and low r2 between the current and
previously published loci (Supplementary Data 3). Multiple
independent signals were observed at BAK1 (2), TKTL1 (2), TERT
(3), DMRT1 (4), and the 19p11-p12 (6) region (Table 1; Supple-
mentary Data 2), a complex region containing multiple KRAB-
zinc finger proteins (Supplementary Fig. 4). Minimal overlap is
present between the 66 novel and replicated independent loci for
TGCT and susceptibility loci identified in GWAS of other cancers
(Supplementary Data 4). Only four (6%) loci were associated with
risk of another cancer type, each with consistency in direction of
effect: BCL2L11 (rs6708784–rs1439287, r2= 0.93) with chronic
lymphocytic leukemia, TERT (rs2735940) with colorectal cancer,
HEATR3 (rs2160570–rs10852606, r2= 0.99) with glioblastoma,
and HNF1B (rs11263762–rs12601991, r2= 1.00) with cancer
(pleiotropy).
Stratified analyses by histology, family history, or cryptorchid-
ism (Supplementary Table 6) did not identify subgroup
associations. All 22 susceptibility signals displayed marked
differences in minor allele frequency between men of European
and African ancestry (Supplementary Table 7) likely explaining
some of the observed racial differences in TGCT risk. The 22
identified loci explain 7.0% of father-to-son heritability and 4.7%
of heritability among siblings, increasing the overall heritability
estimates to 44.0% and 29.1%, respectively.
To generate a polygenic risk score (PRS) for TGCT, we
modeled all 78 identified TGCT susceptibility markers, including
those that did and did not achieve genome-wide significance in
the current study. We found that men in the 95th percentile of
PRS had a 6.8-fold increased disease risk (3.4% lifetime risk)
compared to men with median scores (Fig. 2). This model
identifies men with TGCT with 78.1% accuracy.
Assessment of credible risk variants (CRV). We defined a
credible risk variant (CRV) as a SNP in strong LD (r2 ≥ 0.8) with
any of the 66 novel or replicated signals to determine if among
the set of 4755 CRVs there are potential functional variants that
influence function or expression of the target gene (Supplemen-
tary Table 8 and Supplementary Data 5). A total of 108 unique
genes were in regions demarcated by the CRVs on the autosomes
and X chromosome. Most GWAS have implicated noncoding
variation that work through gene regulation (e.g., enhancers,
promoters), but coding variation can also influence target gene
function. Seventy-three (1.5%) CRVs were located in coding
regions; 34 (0.7%) were synonymous and 39 (0.8%) were mis-
sense variants (Supplementary Data 6). None were predicted to
be pathogenic using REVEL and VEST426,27. Seven (0.1%) CRVs
were annotated at a splice site; but only one, rs1060604 at PMF1
was predicted to influence splicing28. These results align with
those from other GWAS and support that most susceptibility
functional variants affect the regulation of target genes rather
than directly altering gene function.
Inference of autosomal genes associated with TGCT. To iden-
tify highly and moderately likely target genes on autosomes, we
assessed the gene regions delimited by 4484 CRVs corresponding
to 61 top signals (Supplementary Data 5). The total number of
target genes evaluated was 108, corresponding to 101 unique
genes. As further detailed below, we evaluated (i) the number of
genes in the region, (ii) location of the most significantly asso-
ciated signal, (iii) results from colocalization eQTL analysis29, (iv)
gene expression in fetal germ cells30, and (v) results from pro-
moter Capture-C analysis of the TGCT cell line NT2-D1
(NTERA2)31,32 evaluated in conjunction with data from
ATAC-seq (Fig. 3). The number of genes in each region ranged
from one to eight. For 46 (75%) signals, the gene region included
only one or two genes; and for six (10%) signals the gene region
encompassed no genes (Supplementary Data 5). Forty-three
(70%) of the top signals were in an exon, an intron, or within
10 Kb of a start site (Supplementary Data 5). The colocalization
analysis found an eQTL in at least two (non-testis) tissues for 23
(21%) genes, and in testis tissue for 4 (4%) genes (Supplementary
Data 5, 7).
Type 2 TGCTs originate from either fetal primordial germ cells
or gonocytes and then develop from the noninvasive precursor
GCNIS22. In the absence of available RNA sequencing data on
GCNIS, we used single-cell RNA sequencing data from Li et al.30
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to evaluate candidate genes for expression in fetal gonads
measured at various timepoints. We included male and female
germ cells and soma to get a complete picture of the potential
expression of genes that may be influencing TGCT development.
Transcript levels were categorized as low expression (≤698) for 33
(31%) genes, medium expression (699–2348) for 37 (34%) genes,
and high expression (≥2349) for 38 (35%) genes based on tertiles
of expression values (Supplementary Fig. 5; Supplementary
Data 5). We conducted Assay for Transposase-Accessible
Chromatin analysis using sequencing (ATAC-seq) on four TGCT
cell lines (Supplementary Data 8, available at https://genome.ucsc.
edu/s/jpluta/TECAC2020). The CRVs were significantly enriched
in open chromatin regions in all cell lines (EP2102, P= 0.0015;
NT2-D1 [NTERA2], P= 2.63 × 10−10; NCCIT, P= 4.37 × 10−8;
TCAM2, P= 1.04 × 10−14), consistent with a potential effect on
gene regulation. We further evaluated data from ATAC-seq in the
context of promoter Capture-C data available on one of the cell
lines, NT2-D1 to determine whether the promoter region of a
target gene demonstrated a connection with a CRV located in an
open chromatin region. Seventeen (16%) genes demonstrated
these connections (Supplementary Data 5). Connections appear-
ing in two or more cell lines were scored more highly than a
connection found in just one cell line. Based on this evaluation of
the potential target genes on the autosomes, we classified 37
(37%) genes as highly likely, 25 (25%) genes as moderately likely,
and 39 (39%) as unlikely to be associated with TGCT; genes with
multiple classification levels were counted in the highest
likelihood group (Table 1, Supplementary Data 2, 5).
Inference of sex chromosome genes associated with TGCT. On
the X chromosome, we assessed the gene regions delimited by 271
CRVs corresponding to five top signals (Supplementary Table 8).
The total number of unique target genes interrogated was seven.
Due to the absence of available eQTL data for X chromosome
genes and the lack of expression data in fetal gonads for one target
gene, it was not possible to create an equivalent schema to evaluate
candidate target genes on the X chromosome. Still, based on our
Fig. 1 Manhattan plots of markers associated with TGCT risk. Novel markers identified in the current meta-analysis are shown as blue squares ( ) with
lowercase letters corresponding to column 1 of Table 1. Susceptibility markers identified in previous studies that surpassed genome-wide significance (P≤
1 × 10−8) in the current meta-analysis are shown as green circles ( ) with numbers corresponding to column 1 of Supplementary Data 2. Susceptibility
markers identified in previous studies that failed to attain genome-wide significance (P > 1 × 10−8) in the current meta-analysis are shown as red diamonds
( ) with numbers corresponding to column 1 of Supplementary Data 2. a Markers are plotted against a full range y-axis that incorporates rs4474514 at
KITLG (P= 1.42 × 10−154). b Markers are plotted against a partial range y-axis capped at P= 1.42 × 10−40 to allow for better visualization and
discrimination of most associations.
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reduced evaluation scheme, one (14%) gene was scored as highly
likely and two (29%) genes as moderately likely to be associated
with TGCT (Table 1; Supplementary Table 8). However, should
eQTL and expression data become available, the four (57%) genes
unlikely to be associated with TGCT could be scored as highly or
moderately likely (and similarly, the two moderately likely genes
could be scored as highly likely); thus, we considered all genes as
possible target genes (Supplementary Table 8).
Fig. 2 Association of polygenic risk score and TGCT status. Polygenic risk scores (PRS) were calculated for independent samples from n= 5602 men
with TGCT and 5006 men without disease from a model incorporating the 22 novel and 56 previously identified markers and effect size estimates from the
meta-analysis. Odds ratios are relative to the median risk, composed of subjects in 45–55th percentile of PRS. Men in the top 95th percentile had a 6.8-fold
increase (odds ratio (OR)= 6.75, 95% confidence interval (CI) 4.92–9.26; P= 2.84 × 10−32) in risk of developing TGCT compared to men at the 45–55th
percentile. Dashed line indicates OR= 1; error bars represent 95% CI.
Fig. 3 Flow diagram for gene and functional variant inference. Highly and moderately likely target genes were determined by evaluating information
derived from GWAS results (blue) and external data sources (orange) including eQTL and promoter Capture-C analyses, and gene expression in fetal
testis. To explore potential functional variants, Empirical Bayes modeling in PAINTOR (green) was conducted for all credible risk variants after annotation
from multiple publicly available and locally derived data sources.
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Testis-specific gene enrichment. Genes selected for enrichment
analysis included target genes (n= 62) on autosomes that scored
moderately or highly likely to be associated with TGCT and all
target genes (n= 7) on the X chromosome; two of these genes did
not have available expression data. There was enrichment of
testis-specific expression (P= 0.00067) in this gene set with three
genes having at least 5-fold greater expression in testis compared
to all other tissues (Supplementary Fig. 6). The expression of
three other genes was enhanced in testis as indicated by five-fold
or greater expression in testis compared to the average in all other
tissues.
Functional assessment of variants by PAINTOR analysis. We
also explored potential functional variants determined by
PAINTOR, a Baysian approach that combines genetic association,
linkage disequilibrium and enriched genomic features (Fig. 3)33.
We annotated all 4755 CRVs with information from 36 datasets
relevant to TGCT, including publicly available data and locally
generated data from TGCT cell lines (histone marks, open
chromatin marks, transcription factor binding sites, methylation),
adult testis (histone marks, open chromatin marks, transcription
factor binding sites, methylation, transcription start sites),
embryo testis (open chromatin marks), and fetal testis (open
chromatin marks) (Supplementary Table 9; Supplementary
Fig. 7). PAINTOR analysis prioritized 100 variants as potentially
functional, the majority of which had high posterior probabilities
(≥95%); four (4%) variants had a posterior probability between 90
and 95%, and only one (1%) fell below 90%34 (Supplementary
Data 9). Potentially functional variants were found for 57 (86%)
of the 66 top signals. Two top signals, rs55873183 in DMRT1 and
rs17336718 in TKTL1, contained only one CRV and thus could
not be evaluated by PAINTOR. Most variants identified through
the PAINTOR analysis were intronic (67%), one was exonic, and
most (20%) of the remainder fell within 10 kb of the target gene
start site. Of the 102 variants, 83 (81%) disrupted transcription
factor binding sites.
Discussion
Our meta-analysis has increased the number of susceptibility loci
for TGCT by one-third. Men in the 95th percentile of the PRS
have a 6.8-fold increased disease risk compared to men at the
median PRS (Fig. 2); and these men have a 3.4% lifetime risk as
compared to 0.4% in the general population2. The PRS for TGCT
contains fewer SNPs than those available for most other common
cancers, yet with a larger effect. For example, women in the 95th
percentile of the PRS for breast cancer (313 SNPs) had a 2.4-fold
increased disease risk compared to women at the median PRS35.
The performance of the PRS derived from TGCT susceptibility
loci suggests that men at highest risk of disease can be identified.
Evaluation of top association signals from our meta-analysis
identified 65 target genes that were evaluated as moderately or
highly likely to be associated with TGCT. Many of these genes
encode proteins that fall into biological pathways relevant to
TGCT susceptibility, including those that influence male germ
cell specification and migration, sex determination and matura-
tion, and regulation of the mitotic cell (HSA-69618, FDR 8.5 ×
10−5; Fig. 4). For several target genes, findings from murine
models support their direct role in the development of TGCT or
TGCT-related phenotypes.
Deletion variants at the Steel locus (Sl) on the murine 129/Sv
background are associated with increased incidence of TGCT;
and the etiological gene has been demonstrated to be Kitl36,37.
KITLG rs4474514 is the most statistically significant signal in our
meta-analysis with a per-allele odds ratio over 2.0. Multiple other
target genes implicated by top association signals influence male
germ cell development in the mouse. Prdm14 is critical for the
specification of primordial germ cells from somatic cells, parti-
cipating in the reacquisition of potential pluripotency and suc-
cessful epigenetic reprogramming38. The identified region on
12q13.2 contains two candidate target genes, SP1 and AMHR2
(Supplementary Fig. 1n). SP1 is a transcription factor that reg-
ulates cellular processes, including inhibition of mouse embryonic
stem cell differentiation39. eQTL analysis suggest that the
potential functional variant is associated with SP1 upregulation,
thus similarly favoring developmental arrest by maintaining fetal
germ cells in a relatively dedifferentiated state. AMHR2 is the
receptor for anti-Mullerian hormone (AMH) which, in addition
to testosterone (and hence involvement also of AR), results in
male sex differentiation, preventing the development of Mullerian
ducts into the uterus and fallopian tubes40. In the Japanese rice
fish (medaka), knockout of amrh2 is associated with sex reversal
and excessive proliferation of germ cells41.
Although we did not define AR as a moderately or highly likely
target gene due to the lack of available data to inform eQTL
analysis or the evaluation of gene expression in fetal testis, the top
marker at Xq12 suggests that AR may be involved in the etiology
of TGCT. Disruption of AR leads to androgen insensitivity syn-
drome and partial sex reversal, depending on the degree of
disruption42. Furthermore, high linkage disequilibrium (r2= 1)
exists between the AR locus and variants associated with a
decrease in male-pattern baldness43 (Supplementary Data 4), a
phenotype previously associated with risk of TGCT44. Immuno-
histochemical investigations also identified AR protein to be
present in 40–50% of seminoma and GCNIS samples45. Further
evaluation of this gene is warranted, results from which may
further support the long-held hypothesis that a relative decrease
in androgen compared to the overall population contributes to
risk of TGCT46.
We identified a fourth independent susceptibility allele at
DMRT1, which plays a critical role in sex determination and
maintenance of the male somatic niche47. Expression of DMRT1
is enriched in testis tissue. Loss of Dmrt1 on the murine 129/Sv
background leads to an over 90% incidence of testicular ter-
atomas, due to a lack of ability to silence regulators of
pluripotency48,49. Knockout of Dazl, a master transcriptional
regulator essential for spermatogenesis, causes spontaneous
gonadal teratomas, likely due to prolonged expression of plur-
ipotency genes50,51. Expression of DAZL is also enriched in testis
tissue.
BAK1 and BCL2L11 are both members of the BCL-2 family,
which together tightly regulate the mitochondrial apoptotic
response to either facilitate or prevent cell death depending upon
intercellular stimuli52. Bak (BAK1) is a pro-apoptotic effector of
mitochondrial outer membrane permeabilization, which allows
release of cytochrome C and other apoptogenic factors leading to
cell death53. Bim (BCL2L11) is a pro-apoptotic BH3-only protein
that can activate Bak, but preferentially activates pro-apoptotic
effector Bax54,55. Interestingly in mouse models, Bim and Bik
cooperate to initiate early germ cell apoptosis in a biological
pathway that appears to require Bax, but not Bak56. Bax
also controls apoptosis of fetal germ cells during their migration,
and in Bax null mice ectopic germ cells with retained
primitive markers are observed57,58. Further 60% of NestinCre-
Baxfl/flBak−/− mice develop high-grade tumors within the testis
that have expression profiles consistent with germ cell tumors59.
Our eQTL analysis suggests downregulation of BCL2L11,
implying improper survival of arrested germ cells and their
transformation to pre-GCNIS.
We also identified multiple target genes encoding proteins
involved in chromosomal segregation and heterochromatin
organization. Inherited alterations in these genes likely contribute
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to unique hallmarks of TGCT that has one of the highest aneu-
ploidy scores among cancers, characterized by near universal 12p
isochromosome or amplification and frequent genome
doubling60,61. PPP2R5A, a Ser/Thr phosphatase enriched at
kinetochores and regulates chromosome-spindle interactions62, is
an implicated target gene. Similar to AR, CENPI could not be
defined as a top ranking target gene because of lack of available
data for the X chromosome; but the top signal at Xq22.1 suggests
that CENPI, a centromere protein and part of the CENPA-NAC
(nucleosome-associated) complex responsible for chromosome
alignment and segregation and mitotic progression important for
gametogenesis63,64, may play a role in TGCT risk. At 9q34.3 the
29.5 kb haplotype block (rs28393706) contains two putative
effector genes with overlapping promoter regions, ANAPC2, an
E3 ligase enzyme that promotes metaphase-anaphase transition
as part of the anaphase-promoting complex (APC), and SSNA1
(SS nuclear autoantigen 1), a centrosomal protein regulating the
microtubule-severing activity of spastin65,66. Six implicated genes
(PMF1, PPP2R5A, ANAPC2, SSNA1, TEX14, andMCM3AP) have
an eQTL associated with downregulation, consistent with a more
permissive phenotype for chromosomal mis-segregation; and
expression of TEX14 is enriched in testis tissue. Further, multiple
TGCT-implicated proteins in the chromosomal segregation
pathway interact with TGCT-implicated male germ cell devel-
opment proteins, demonstrating a biological network underlying
TGCT susceptibility (Fig. 4).
After pathway analysis of moderately and highly ranking target
genes, several were found to encode proteins that interact in
mRNA translation, including one of the ribosomal proteins
(RPL4), translation termination protein eRF3A (GSTP1) and
translocon-associated protein subunit gamma (TRAP-gamma,
encoded by SSR3), which is the general ribosomal interactor
participating in the co-translational translocation of proteins into
the endoplasmic reticulum67. Finally, multiple DNA-binding
transcription factors are implicated in TGCT susceptibility,
including HNF1B, PITX1, PKNOX2, PRDM14, SP1, TFCP2L1,
ZFPM1, ZNF64, and ZNF217. Several are zinc finger proteins
(ZNF) (including KRAB-ZNF) critical for proper germ cell
development, such as male primordial germ cells specification
and epigenetic reprogramming68.
Results from our investigation provide further understanding
of the genetic architecture of TGCT, enhance comprehension of
Fig. 4 Interaction of proteins in the germ cell development and chromosomal segregation pathways. A protein–protein interaction network for the germ
cell development and chromosomal segregation pathways was created using STRING (string-db.org). Proteins encoded by genes implicated as associated
with TGCT susceptibility in these pathways are shown, and line weights indicates the degree of confidence of interaction between any two proteins.
*GATA4, a previously identified TGCT susceptibility locus, did not reach genome-wide statistical significance in our current study. **PCNT was evaluated as
a low likelihood target gene.
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the biology of male germ cell development, and highlight biolo-
gical pathways important to TGCT that are not noted in other
cancers. Our findings implicate potentially important pathways,
including regulation of apoptosis beyond the BAK1-BCL2L11
axis (AIFM3, CLPTM1L), enzymatic functions (MPV17L, TKTL1,
and UCK2) and several genes involved in actin, cytoskeleton, and
microtubule organization (CYTH1, ENOSF1, TNXB, and
ARL14EP). The latter may contribute to errors in germ cell
migration or chromosomal segregation, likely enhancing the
dysregulation of genes directing the germ cell-somatic niche
interaction during early development (KITL, DMRT1).
Our meta-analysis has identified 66 validated susceptibility loci
for TGCT. Many of these loci have a stronger effect size than
those observed in adult epithelial cancers, which results in a high
fraction of explained heritability of TGCT. Many TGCT risk
alleles have higher frequencies in men of European compared to
African genetic ancestry, concordant with the known difference
in disease incidence between these groups. Importantly, we have
established a PRS that identifies men at highest risk of disease.
This TGCT PRS could be potentially applied in men with other
risk factors, such as cryptorchidism or infertility, to be targeted
for early detection and disease mitigation.
Methods
Data sources. We procured existing data from five genome-wide association
studies of TGCT from 3557 men with TGCT and 13,970 without disease10,12,18,21
previously published as a meta-analysis9 (Supplementary Table 1); from 300 men
with TGCT and 151,991 men without disease provided by deCODE genetics
(Reykjavik, Iceland); and from 697 men with TGCT and 8716 men without disease
available from the UK Biobank. We completed de novo genome-wide genotyping
on 5969 men with TGCT and 5261 without disease ascertained through 14 studies
(Supplementary Table 2) from Canada (Princess Margaret Hospital, Toronto), Italy
(University of Padova, Padova; University of Turin, Turin), Germany (University
Medical Center Hamburg, Hamburg), Netherlands (University Medical Center
Groningen, Groningen; Radboud University, Nijmegen), Norway (Cancer Registry
of Norway, Oslo; Oslo University Hospital; Oslo), Sweden (Karolinska Institutet,
Stockholm), United Kingdom (University of Leeds, Leeds), and the United States
(Fred Hutchinson Cancer Research Center, Washington; MD Anderson Cancer
Center, Texas; University of Pennsylvania, Pennsylvania; University of Southern
California, California; Yale University, Connecticut) termed ‘TECAC’. We also
completed de novo targeted SNP genotyping on 481 men with TGCT and 376 men
without disease from Spain (Spanish National Cancer Research Centre, Spain) and
277 men with TGCT and 289 men without disease from Pennsylvania (University
of Pennsylvania) and 281 men with TGCT and 733 men without disease from 14
TECAC centers whose samples failed pre-genome-wide genotyping quality control
(Supplementary Table 3).
Genotyping. TECAC samples were genotyped on the Illumina Infinium
HumanCore-24 BeadChip array, which included a genome-wide backbone of
306,670 SNPs plus custom content of 6290 SNPs for a total of 312,960 genetic
markers. Custom content of 7118 SNPs passing initial Illumina quality control was
composed of 5598 SNPs from our previous meta-analysis with genome-wide sig-
nificance 1 × 10−5 ≥ P > 5 × 10−811 and 1520 additional SNPs related to testicular
cancer and associated phenotypes. Apart from samples from MD Anderson Cancer
Center (2.9%), genotyping was centralized at the Center for Applied Genomics
(CAG; University of Pennsylvania, Children’s Hospital of Philadelphia, Philadel-
phia, PA). Following standard quality control, subjects were excluded because of
discordant or ambiguous chromosomal sex, relatedness (IBD > 0.1875), excessive
heterozygosity (>3 standard deviations from the mean), low genotype call rate
(<98%), or non-European genetic ancestry as determined by principal component
analysis (PCA). Quality control was performed using PLINK v1.09 (Purcell et al.,
2007), and principal components were calculated using EIGENSOFT v6.1.469,70.
Subjects were plotted against the first two principal components and genetic
clusters were determined by k-means clustering; those greater than six standard
deviations from the center of the European cluster were removed (n= 581; Sup-
plementary Fig. 8). Subjects with missing information on case status were excluded.
SNPs were excluded because of low genotype call rate (< 99%), differential miss-
ingness by case status (P < 0.00001, Fisher’s exact test), differential missingness by
DNA source (blood or saliva; P < 0.00001, Fisher’s exact test), Hardy-Weinberg
equilibrium (P < 0.00001, Fisher’s exact test), duplicate physical position, or minor
allele frequency < 0.01. To account for potential batch effects, we also removed
SNPs with >10% difference in MAF comparing samples genotyped at MD
Anderson to the CAG. After quality control, 10,608 individuals and 246,186 SNPs
remained. Genome-wide imputation was performed using the Haplotype Reference
Consortium Panel r1.1 (HRC)71. Phasing (Eagle2 v2.4.172) and imputation
(minimac4 v1.0.073) were conducted automatically on the Michigan Imputation
Server (https://imputationserver.sph.umich.edu). Imputed SNPs were screened for
MAF, HWE, missingness, and imputation quality (INFO > 0.3).
Targeted genotyping. Based on results from genotyping and imputation (see
below, Genotype analysis and meta-analysis), 46 SNPs were brought forward for
targeted genotyping; dbSNP was used to confirm SNP details. DNA was isolated
from 2500 samples using Agencourt beads system (Beckman-Coulter), quantified
on the Spectramax (Molecular Device) reader using Quant-iT™ PicoGreen® dsDNA
Assay Kit, and genotyped on a Fluidigm 192.24 Dynamic Array Integrated Fluidic
Circuit in the nanofluidic SNP genotyping system, SNPtype assay (Fluidigm Corp.,
CA), which employs allele-specifically designed fluorescencent (FAM or VIC)
primers and a common reverse primer. SNP arrays were thermal cycled (Juno
instrument), and the endpoint fluorescent values were measured on Biomark™
system. Final sample genotype calls and quality control were acquired using
Fluidigm SNP Genotyping Analysis software. Subjects were removed for excess
heterozygosity (>3 standard deviation from the mean) and genotype missingness
(≥10%). SNPs were screened for genotype missingness (>2%), differential miss-
ingness (P < 0.001), and minor allele frequency (<0.01). After quality control, 1039
men with TGCT and 1398 men without disease remained (Supplementary
Table 3).
Genotype analysis and meta-analysis. Logistic regression was used to determine
associations between TGCT status and genotype, assuming an additive genetic
model. Regression models were implemented in SNPTEST v2.574, and included the
first three PCs and a categorical variable representing study center as covariates.
Summary statistics from existing genome-wide association studies were combined
using a fixed-effects model implemented in METAL (r. 2018-08-28)75, with each
coefficient estimate weighted by the inverse of its variance (Supplementary Data 1,
3). To account for different coverage of the various reference panels, only SNPs that
were present in all studies were considered. Multiallelic variants and SNPs
demonstrating study heterogeneity (P < 0.001, Cochran’s Q test) were removed. We
then selected the 60 top ranking previously unreported SNPs that were strongly
associated (P < 5 × 10−6) with TGCT case status for targeted genotyping. Of these
60, 46 passed in silico and initial quality testing for Fluidigm primer specificity.
Each SNP was tested for its association with TGCT, adjusted for study center.
Results were combined with study-specific estimates derived from genome-wide
genotype data (above) using METAL. Overall summary odds ratios and corre-
sponding 95% confidence intervals were obtained. Associations with P ≤ 5 × 10−8
were considered statistically significant.
Validation of imputed genotypes. TECAC subjects with genome-wide genotyp-
ing were rank-ordered based on the total number of minor alleles at the 46 SNPs
represented on the targeted genotyping panel. We selected the top 500 subjects,
assuring at least 10% representation of the minor allele for each SNP, for geno-
typing on the targeted panel. Two subjects were removed for missingness, and one
for excessive heterozygosity, leaving 497 subjects (267 cases, 230 controls). The
correlation coefficient between observed genotype on the targeted panel and
imputed genotype inferred from genome-wide genotyping for 36 susceptibility loci
was calculated. The average concordance was 0.96 (0.93, 0.99) (Supplementary
Table 4).
Independence analysis. For genetic regions with more than one SNP that reached
genome-wide significance, we conducted conditional and joint (COJO) multiple-
SNP analysis using GCTA v1.26.076 to determine independence of each SNP
marker. We used the summary statistics from our meta-analyses and individual-
level SNP data from TECAC subjects to estimate pairwise linkage disequilibrium
(Supplementary Table 5). For each region of interest, the most significant (i.e.,
reference) SNP was jointly modeled with each other ‘test’ SNP in the region. If the
test SNP retained genome-wide significance in the joint model, it was deemed
independent. This procedure was performed iteratively, adding the most highly
significant independent SNP to the model at each step, ending when there were no
more independent SNPs that reached genome-wide significance. SNPs were further
interrogated by visualizing results in LocusZoom v1.4 and custom independence
plots written in R.
Stratified analysis. We conducted analyses stratified by family history of TGCT,
tumor subtype (seminoma, nonseminoma, mixed), and cryptorchidism, for those
studies and case subjects with available data (Supplementary Table 6). Associations
were determined using an analytic pipeline mirroring the main analysis. In the
analysis of tumor subtype, SNPs with a MAF < 0.05 were removed as were variants
with study heterogeneity exceeding P < 0.05 by Cochran Q. In the analyses of
family history and cryptorchidism, SNPs with a MAF < 0.05 were removed and
only variants for which all study-specific effects were in the same direction were
retained; and we did not rely on Cochran Q to test for study heterogeneity because
of reduced power to detect differences.
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Heritability. We estimated heritability of a given SNP as the proportion of the total
phenotypic variance explained by the SNP. The phenotypic variance can be con-
sidered the sum of genetic and environmental effects, which can be approximated
from the familial relative risk. We used a derived value of four for the relative risk
(RR) for affected fathers and eight for brothers77. With the RR represented by λ,
heritability is then calculated as:
h ¼ β
2*2f ð1 f Þ
logðλ2Þ ð1Þ
where β is the estimated log-odds ratio of the SNP, and f is the frequency of the
effect allele.
Polygenic risk score. A polygenic risk score (PRS) consisting of the 22 novel and
56 previously identified susceptibility loci was calculated for 5602 men with TGCT
and 5006 men without disease (Supplementary Table 2) using PLINK v1.09. The
previously published data was only used in the calculation of effect sizes, as raw
genotype data were not available, and to avoid bias from chip or batch effects. The
number of risk alleles was multiplied by the effect size from the meta-analysis and
summed across all risk loci. A lifetime risk of 0.5% for TGCT was assumed, which
accounted for the range of risks over the countries included in the current study
(e.g., lifetime risks in the United States 0.4%, United Kingdom 0.53%, Netherlands
0.64%, and Denmark 0.82%)78. The out-of-sample accuracy of the PRS was
determined by leave-one-out cross validation of the area under the receiver-
operator curve, which reflects the probability that the PRS can accurately predict
TGCT status in a random subject.
SNP associations with race and other GWAS studies. For the 22 identified loci,
the variant frequency of most strongly associated SNP was downloaded from
dbSNP (gnomAD—Genomes Accession: PRJNA398795 ID: 398795) for European
(SAMN10181265), African (SAMN07488254) and East Asian (SAMN07488251)
groups. Comparisons of risk allele frequencies were done using two-tailed Fisher’s
Exact test (Supplementary Table 7). To determine associations with other GWAS
studies, we used the suite of applications within LDLink79–81, using an LD of r2 >
0.80 (Supplementary Data 4).
Credible risk variants (CRVs). CRVs were defined to include all SNPs with LD of
r2 ≥ 0.80 of the most strongly associated SNP in each locus, using the European
population in the HRC. LD was estimated using GCTA. CRVs were annotated with
NCBI’s hg19 RefSeq database using ANNOVAR r. 2019-10-2482.
Colocalization analysis. For each GWAS locus, we used colocalization to find
evidence that the GWAS signal at that locus could be explained by an eQTL signal.
We used publicly available data from the GTEx consortium for this analysis. GWAS
summary statistics were converted from hg37 to hg38 using LiftOver (https://
genome.ucsc.edu/cgi-bin/hgLiftOver), resulting in a loss of 1,284,722 variants
(6.0%). For each phenotype, colocalization analysis was run in windows across the
genome separately for each of the 49 tissues in GTEx v883. We first identified
previously defined LD blocks for the genome84 with a sentinel SNP at P < 5 × 10−8,
and restricted colocalization analysis to these LD blocks. For each LD block with a
sentinel SNP, all genes within 1Mb of the sentinel SNP (cis-Genes) were identified,
and then restricted to those that were identified as eGenes in GTEx v8 (cis-eGenes).
For each cis-eGene, colocalization analysis was performed using all variants within
1Mb of the gene. A significant colocalization29 was defined as PP3+ PP4 > 0.8 and
PP4/(PP3+ PP4) > 0.9 (Supplementary Data 7).
We and others have shown that colocalization analyses are most informative
when performed across a diverse set of tissues and datasets85. Although the GTEx
data are quite comprehensive, there are varying sample sizes across the 50 sampled
tissues and eQTL effects are often shared across multiple tissues85. As a result, the
power to detect eQTL-GWAS colocalizations varies by tissue, and multi-tissue
analyses can discover more informative eQTL-GWAS colocalizations than analyses
that rely on a single dataset or tissue. Thus, we do not rely solely on adult testis
tissue for identifying eQTLs of interest, especially as it contains multiple tissue types
and adult germ cells rather than primordial germ cells, the cells of origin for TGCT.
ATAC-seq library generation and peak calls. Live cells from the TGCT cell lines
were harvested via trypsinization, followed by a series of wash steps. 100,000 cells
from each sample were pelleted at 550 × g for 5 min at 4 °C. The cell pellet was then
resuspended in 50 μl cold lysis buffer (10mM Tris-HCl, pH 7.4, 10mM NaCl, 3mM
MgCl2, 0.1% IGEPAL CA-630) and centrifuged immediately at 550 × g for 10min at
4 °C. The nuclei were resuspended in the transposition reaction mix (2× TD Buffer
(Illumina Cat #FC-121–1030, Nextera), 2.5 µl Tn5 Transposase (Illumina Cat #FC-
121–1030, Nextera), and Nuclease Free H2O) on ice and then incubated for 45min at
37 °C. The transposed DNA was then purified using the MinElute Kit (Qiagen), eluted
with 10.5 μl elution buffer. The transposed DNA was PCR amplified using Nextera
primers for 12 cycles to generate each library. The PCR reaction was subsequently
cleaned up using AMPureXP beads (Agencourt) and libraries were paired-end
sequenced on the Illumina NovaSeq platform. Open chromatin regions were called
using the ENCODE ATAC-seq pipeline (https://www.encodeproject.org/atac-seq/),
selecting the resulting conservative irreproducible discovery peaks (with all coordi-
nates referring to hg19). Each cell line was evaluated in triplicate. We defined a
genomic region open if it had 1 bp overlap with an ATAC-seq peak.
Cell fixation for chromatin capture. The protocol used for cell fixation was in line
with previous methods86. NT2-D1 cells were collected and single-cell suspension
were made with aliquots of 10 million cells in 10 mL media. Five hundred forty
microliters (37%) formaldehyde was added and incubated for 10min at RT on a
platform rocker. The reaction was quenched by adding 1.5mL 1M cold glycine
(4 °C) for a total volume of 12 mL. Fixed cells were centrifuged at 1000 rpm for
5 min at 4 °C and supernatant removed. The cell pellets were washed in 10mL cold
PBS (4 °C) followed by centrifugation as above. Supernatant was removed and cell
pellets were resuspended in 5mL of cold lysis buffer (10mM Tris pH8, 10 mM
NaCl, 0.2% NP-40 supplemented with protease inhibitor cocktails). Resuspended
cells were incubated for 20min on ice, centrifuged as above, and the lysis buffer
removed. Finally, cell pellets were resuspended in 1 mL fresh lysis buffer, transferred
to 1.5mL Eppendorf tubes and snap frozen (ethanol/dry ice or liquid nitrogen).
Cells were stored at −80 °C until they were thawed for 3 C library generation.
3C library generation and promoter Capture-C. We used standard methods for
generation of 3 C libraries31,32. For each library, 107 fixed cells were thawed at 37 °C,
followed by centrifugation at RT for 5 min at 1845 × g. The cell pellet was resuspended
in 1mL of dH2O supplemented with 5 μL 200× protease inhibitor cocktail, incubated
on ice for 10min, then centrifuged. The cell pellet was resuspended to a total volume
of 650 μL in dH2O. Fifty microliters of cell suspension was set aside for predigestion
QC, and the remaining sample was divided into three tubes. Both predigestion
controls and samples underwent a predigestion incubation in a Thermomixer
(BenchMark) with the addition of 0.3%SDS, 1× NEB DpnII restriction buffer, and
dH2O for 1 h at 37 °C shaking at 1000 rpm. A 1.7% solution of Triton X-100 was
added to each tube and shaking was continued for another hour. After predigestion
incubation, 10 μl of DpnII (NEB, 50 U/µL) was added to each sample tube only and
continued shaking along with predigestion control until the end of the day. An
additional 10 µL of DpnII was added to each digestion reaction and digested over-
night. The next day, a further 10 µL DpnII was added and continue shaking for
another 2–3 h. 100 μL of each digestion reaction was then removed, pooled into one
1.5 mL tube, and set aside for digestion efficiency QC. The remaining samples were
heat inactivated incubated at 1000 rpm in a MultiTherm for 20min at 65 °C to
inactivate the DpnII and cooled on ice for 20 additional minutes. Digested samples
were ligated with 8 μL of T4 DNA ligase (HC ThermoFisher, 30U/µL) and 1× ligase
buffer at 1000 rpm overnight at 16 °C in a MultiTherm. The next day, an additional
2 µL of T4 DNA ligase was spiked into each sample and incubated for another few
hours. The ligated samples were then decrosslinked overnight at 65 °C with Proteinase
K (20mg/mL, Denville Scientific) along with predigestion and digestion control. The
following morning, both controls and ligated samples were incubated for 30min at
37 °C with RNase A (Millipore), followed by phenol/chloroform extraction, ethanol
precipitation at −20 °C, the 3 C libraries were centrifuged at 85 × g for 45min at 4 °C
to pellet the samples. The controls were centrifuged at 1845 × g. The pellets were
resuspended in 70% ethanol and centrifuged as described above. The pellets of 3 C
libraries and controls were resuspended in 300 and 20 μL dH2O, respectively, and
stored at −20 °C. Sample concentrations were measured by Qubit. Digestion and
ligation efficiencies were assessed by gel electrophoresis on a 0.9% agarose gel and also
by quantitative PCR (SYBR green, Thermo Fisher).
The promoter Capture-C approach was designed to leverage the four-cutter
restriction enzyme DpnII in order to give high-resolution restriction fragments of a
median of ~250 bp31,32. Custom capture baits were designed using Agilent
SureSelect RNA probes targeting both ends of the DpnII restriction fragments
containing promoters for coding mRNA, noncoding RNA, antisense RNA, snRNA,
miRNA, snoRNA, and lincRNA transcripts (UCSC lincRNA transcripts and sno/
miRNA under GRCh37/hg19 assembly) totaling 36,691 RNA baited fragments
through the genome86. In this study, the capture library was reannotated under
gencodeV19 at both 1-fragment and 4-fragment resolution and is successful in
capturing 89% of all coding genes and 57% of noncoding RNA gene types. The
missing coding genes could not be targeted due to duplication or highly repetitive
DNA sequences in their promoter regions.
Isolated DNA from 3 C libraries was quantified using a Qubit fluorometer (Life
Technologies), and 10 μg of each library was sheared in dH2O using a QSonica
Q800R to an average fragment size of 350 bp. QSonica settings used were 60%
amplitude, 30 s on, 30 s off, 2 min intervals, for a total of five intervals at 4 °C. After
shearing, DNA was purified using AMPureXP beads (Agencourt). DNA size was
assessed on a Bioanalyzer 2100 using a DNA 1000 Chip (Agilent) and DNA
concentration was checked via Qubit. SureSelect XT library prep kits (Agilent) were
used to repair DNA ends and for adaptor ligation following the manufacturer
protocol. Excess adaptors were removed using AMPureXP beads. Size and
concentration were checked by Bioanalyzer using a DNA 1000 Chip and by Qubit
fluorometer before hybridization. One microgram of adaptor-ligated library was
used as input for the SureSelect XT capture kit using manufacturer protocol and
our custom-designed 41 K promoter Capture-C library. The quantity and quality of
the captured library was assessed by Bioanalyzer0a high sensitivity DNA Chip and
by Qubit fluorometer. SureSelect XT libraries were then paired-end sequenced on 8
lanes of Illumina Hiseq 4000 platform (100 bp read length).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-24334-y ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:4487 | https://doi.org/10.1038/s41467-021-24334-y |www.nature.com/naturecommunications 9
Analysis of Capture-C data. Quality control of the raw fastq files was performed
with FastQC. Paired-end reads were preprocessed with the HiCUP pipeline60, with
bowtie2 v2.4.2 as aligner and hg19 as reference genome. Significant promoter
interactions at 1-DpnII fragment resolution were called using CHiCAGO v3.1287
with default parameters except for binsize which was set to 2500. Significant
interactions at 4-DpnII fragment resolution were also called with CHiCAGO using
artificial *.baitmap and *.rmap files where DpnII fragments were grouped into four
consecutively and using default parameters except for removeAdjacent which was
set to False. We define PIR a promoter-interacting region, irrespective of whether it
is a baited region or not. The CHiCAGO function peakEnrichment4Features was
used to assess enrichment of genomic features in promoter-interacting regions at
both 1-fragment and 4-fragment resolution.
ATAC-seq and high-resolution promoter Capture-C variant to gene mapping.
We first identified all proxy SNPs in LD (r2= 0.4) with the sentinel GWAS SNPs
using SNiPA v3.4 (https://snipa.helmholtz-muenchen.de/snipa3/) with the fol-
lowing parameters: population= European; genome annotation= Ensembl 87;
genotype database= 1000 Genomes Phase 3 v5; and genome assembly=GRCH37/
hg19. We then assessed which of these proxy SNPs and which of the gene pro-
moters baited in our Capture-C library resided in an open chromatin region in
NT2-D1, by intersecting their genomic positions with those of the ATAC-seq peaks
(using the BEDTools function intersectBed with 1 bp overlap). Finally, we exported
the chromatin loops linking open proxy SNPs and open gene promoters in the
NT2-D1 Capture-C dataset using only the 4-fragment resolution to increase power.
Scoring of target genes. We devised a scoring system to determine target genes
within gene regions demarcated by CRVs based on a published computational
pipeline, integrated expression quantitative trait and in silico prediction of GWAS
targets (INQUISIT)34. Due to the paucity of data available for TGCT, we modified
the scoring system such that each gene was scored on (i) the number of genes in the
region [2= one gene; 1= two or more genes; 0= no genes]; (ii) location of most
significantly associated signal [1= exonic, intronic, or within ±10 Kb of a gene];
(iii) results from colocalization eQTL analysis29 [1= two or more in non-testis
tissue; 0.5= one in non-testis tissue; 0= none in non-testis tissue; and +1= one in
testis tissue]; (iv) gene expression in fetal germ cells based on tertiles of expression
levels available from Li et al.30 [1= high; 0.5=medium; 0= low;] (Supplementary
Fig. 6); and (v) results from NT2-D1 promoter Capture-C analysis evaluated in
conjunction with data from ATAC-seq in four TGCT cell lines [1= connection in
two or more cell lines; 0.5= connection in one cell line; 0= no connections].
Target genes were then categorized a highly likely [score ≥ 3.0), moderately likely
(score= 2.0 or 2.5), or unlikely (score ≤ 2.0) to be associated with TGCT.
Testis-specific gene enrichment. For the set of target autosomal genes that
scored moderately or highly likely to be associated with TGCT and all target genes
on the X chromosome, we determined tissue-specific gene expression using
MAGMA v1.07 as implemented in FUMA v1.3.588 (Supplementary Fig. 5); 67
genes had expression data available in GTeX. Testis-specific enrichment for this
gene set was determined using the TissueEnrich v1.10.0 R package89. Genes with a
minimum of 1 TPM and five-fold or higher expression in testis tissue compared to
any other tissues were considered testis-enriched; gene not reaching the definition
of testis-enriched, but with a minimum of 1 TPM and five-fold or higher
expression in testis tissue compared to the average in all other tissues were con-
sidered testis-enhanced.
PAINTOR analysis. We downloaded 36 unique datasets with information on
methylation, open chromatin marks, histone marks, and transcription factor
binding sites, i.e., features, in testis tissue or cell lines from ENCODE90 (Supple-
mentary Table 9). All CRVs were annotated with these data and with locally
derived data from ATAC-seq on four TGCT cell lines (2102EP, TCAM2, NT2-D1,
NCCIT); methods described below. For each locus, all features that showed evi-
dence of association (P < 0.15) were assessed for independence (r2 < 0.4). A
likelihood-ratio test was used to determine if independent features yielded a sta-
tistically significant improvement in fit over a model without any features (P <
0.05). The selected features were entered into an Empirical Bayes model (Prob-
abilistic Annotation Integrator, PAINTOR v3.033,91,92 that was additionally
informed by SNP association test statistics and linkage disequilibrium (LD). The
model returned the likelihood that a given SNP was functional, for each SNP in the
CRV (Supplementary Data 9, Supplementary Fig. 7).
Transcription factor binding. We annotated all potential causal variants identified
by PAINTOR and the two top signals with only one CRV in the region (n= 102)
with transcription factor binding motifs (Supplementary Data 9). For each allele,
we analyzed the matrix values, which also allows a determination of whether the
disruption is strong or weak. Analysis was performed using the R package
motifbreakerR v2.4.093.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The meta-analysis data are uploaded under dbGaP phs001349.v1.p1 [https://www.ncbi.
nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001307.v1.p1] (Meta-Analysis
of Five Genome-Wide Association Studies of TGCT) and the replication data under
phs001349.v2.p1 [https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.
cgi?study_id=phs001349.v2.p1] (NCI Testicular Germ Cell Tumors Post GWAS).
Summary statistics for the top 10,000 SNPs are available in Supplementary Data 10.
UKBiobank data are available to all bona fide researchers upon data access application at
http://www.ukbiobank.ac.uk/register-apply/. We obtained them under application
number 3071 to Professor D. Timothy Bishop. The Icelandic population WGS data have
been deposited at the European Variant Archive under accession code PRJEB15197.
Access to the deCODE WGS is restricted due to Icelandic law and the regulations of the
Icelandic Data authority, which prohibits the release of individual-level and personally
identifying data. Requests for access may be submitted to deCODE directly by contacting
B.V.H. (bjarni.halldorsson@decode.is) or K.S. (kstefans@decode.is). Access to these data
can be granted only at the facilities of deCODE genetics in Iceland, subject to Icelandic
laws regarding data usage. The ATAC-seq data and ENCODE data for PAINTOR
analysis are included on a UCSC browser custom track at: https://genome.ucsc.edu/s/
jpluta/TECAC2020. ATAC-seq and Capture-C data are uploaded to the Gene Express
Ominbus (GEO) under accession number GSE175368. The remaining data are available
within the Article, Supplementary Information, or from the authors upon request.
Code availability
The code used in the analysis of this data is available at: https://github.com/nathanson-
lab/TGCT_2021_NatureCommunications. Code used in the analysis is available at
https://doi.org/10.5281/zenodo.4630810.
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